Showing 621 - 640 results of 1,765 for search '(( 10 ((per decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( 12 c decrease ))*', query time: 0.14s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627

    CLINICAL AND ECONOMIC IMPACT OF GENETIC AND NON-GENETIC FACTORS ON INR NORMALIZATION IN PRE-OPERATIVE MANAGEMENT OF WARFARIN PATIENTS by ELJILANY, ISLAM AHMED SAYED AHMED

    Published 2021
    “…To optimize the period of preprocedural warfarin interruption to decrease the incidence of bleeding in case of bridging and the incidence of thromboembolism in case of non-bridging, a study was conducted to determine the influence of CYP2C9, VKORC1, CYP4F2, FII, and FVII genetic polymorphisms and non-genetic factors on INR decline in a cohort of Arabs undergoing a procedure that requires warfarin interruption and developing an algorithm to tailor the duration of warfarin interruption before the procedure. …”
    Get full text
  8. 628
  9. 629
  10. 630

    Study of performance, combustion, and emissions parameters of DI-diesel engine fueled with algae biodiesel/diesel/n-pentane blends by Elkelawy, Medhat

    Published 2021
    “…Due to the disadvantages of using pure biodiesel in engines, it was used as B50 (a blend of 50% diesel and 50% biodiesel). To enhance engine performance, n-pentane was used in different extents of 5, 10, and 15 ml per liter as an enhancer additive. …”
    Get full text
    Get full text
  11. 631
  12. 632

    Solely abluminal drug release from coronary stents could possibly improve reendothelialization by Zhang, Haijun

    Published 2016
    “…LLL of BPSES-A and BPSES-C were 0.63 ± 0.53 and 0.69 ± 0.24 mm, respectively, after 12 weeks. …”
    Get full text
    Get full text
  13. 633
  14. 634
  15. 635
  16. 636
  17. 637
  18. 638
  19. 639

    Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus by Dimitrios, Patoulias

    Published 2023
    “…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
    Get full text
    Get full text
    Get full text
  20. 640